We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+11.19%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$510M
AUM Growth
+$94.9M
Cap. Flow
+$120M
Cap. Flow %
23.47%
Top 10 Hldgs %
49.51%
Holding
57
New
17
Increased
16
Reduced
7
Closed
15

Top Buys

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$22.4M
2
OPTN
OptiNose
OPTN
+$20M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.6M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$17.1M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$13.5M

Top Sells

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$18.9M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$13.1M
3
ALKS icon
Alkermes
ALKS
+$11M
4
BBIO icon
BridgeBio Pharma
BBIO
+$10.4M
5
TVTX icon
Travere Therapeutics
TVTX
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
51
Replimune Group
REPL
$941M
– –
-390,000
Closed -$6.74M
RLMD icon
52
Relmada Therapeutics
RLMD
$557M
– –
-510,000
Closed -$18.9M
SLN
53
Silence Therapeutics
SLN
$495M
– –
-68,915
Closed -$692K
SYRE icon
54
Spyre Therapeutics
SYRE
$8.54B
– –
-100,000
Closed -$1.31M
PVLA
55
Palvella Therapeutics
PVLA
$1.99B
– –
-24,568
Closed -$2.26M
NGM
56
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-316,256
Closed -$4.14M
TCDA
57
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-870,000
Closed -$9.12M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Great Point Partners held 57 positions worth $510M, up 23% from $415M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Great Point Partners deployed $120M of net new capital in Q4 2022, opening 17 new positions and adding to 16 existing holdings. Its largest new stake was OptiNose: 526,316 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Alkermes, an estimated $11M trimmed.

  • Great Point Partners's largest Q4 2022 buy was OptiNose: 526,316 shares worth $14.6M.
  • Great Point Partners added most to RAPT Therapeutics in Q4 2022, an estimated $22.4M increase.
  • Great Point Partners's biggest Q4 2022 reduction was Alkermes, cutting an estimated $11M.
  • Great Point Partners fully exited Relmada Therapeutics in Q4 2022, selling an estimated $18.9M.
  • Great Point Partners's ten largest holdings make up 50% of its $510M portfolio in Q4 2022.
  • Great Point Partners opened 17 new positions and closed 15 in Q4 2022.
  • Great Point Partners's portfolio value rose 23% quarter-over-quarter to $510M.

Based on Great Point Partners's 13F filing for Q4 2022, filed 14 Feb 2023.